Compare SaaS Products

Granza Bio is a biotechnology company developing a novel delivery "shell" platform to direct therapeutic cargo to specific tissues. Their proprietary delivery vehicles are designed using non-immunogenic proteins equipped with a targeting receptor, achieving targeted tropism to organs of interest. These vehicles offer higher stability than conventional lipid nanoparticles (LNPs) and can encompass a variety of cargo, including proteins, DNA, and RNA. For their lead candidate, Granza Bio is leveraging the discovery of the immune system's powerful suite of weapons, "attack particles". Utilizing their advanced delivery platform, they aim to target these "attack particles" against a range of diseases such as cancer, autoimmune disorders, and infections. Interested to know more? Get in touch info@granzabio.com!

Heart failure impacts millions worldwide and is associated with poor quality of life and high mortality rates. Because the heart cannot pump efficiently, fluids buildup around the body. Fluid overload is the main driver behind patient symptoms (shortness of breath, fatigue, chest pain, etc.) and hospitalizations. Our minimally invasive device leverages the body's innate fluid management system to offload trapped fluid and prevent subsequent rounds of buildup. The one-time procedure has sustained effect -- keeping patients healthier, happier, and out of the hospital.